Coletti Kristen D, Bagdure Dayanand N, Walker Linda K, Remy Kenneth E, Custer Jason W
Department of Pediatrics, Pediatric Residency Program, Johns Hopkins University, Baltimore, Maryland.
Division of Pediatric Critical Care, Department of Pediatrics, University of Maryland, Baltimore, Maryland.
Respir Care. 2017 Aug;62(8):1023-1029. doi: 10.4187/respcare.05153. Epub 2017 Jun 6.
High-flow nasal cannula (HFNC) is increasingly utilized in pediatrics, delivering humidified air and oxygen for respiratory conditions causing hypoxia and distress. In the neonatal ICU, it has been associated with better tolerance, lower complications, and lower cost. Few data exist regarding indications for use and the epidemiology of disease/pathology that warrants HFNC in the pediatric ICU.
This study is a retrospective cohort study of patients admitted to a tertiary children's hospital pediatric ICU and placed on HFNC from October 1, 2011 to October 31, 2013. Descriptive statistics were used to describe demographics and utilization data. test comparisons were used for comparison data.
Over the enrollment study period, 620 subjects with HFNC were managed, which represented 27% of total ICU admissions. The average age was 3.74 y (range 0-18.1 y), and subjects were 44% female and 65% African American. Reported primary indications for the utilization of HFNC were status asthmaticus (24%), status asthmaticus with pneumonia (17%), and bronchiolitis (16%). Of the subjects admitted with a primary diagnosis of status asthmaticus, 41% required management with terbutaline. Respiratory viral infections were detected by polymerase chain reaction in 334 subjects managed with HFNC (53.8%) and included 260 subjects testing positive for rhinovirus/enterovirus. When compared with all other respiratory viral illness, subjects with rhinovirus/enterovirus required a higher peak flow (14.9 L vs 13.1 L, = .01); however, this was an older population, and peak oxygen concentration did not differ between the 2 groups (49.8% vs 47.1%, = .25). HFNC was used as postextubation support in 16% of the subjects. Of the 63 subjects with congenital heart disease, 92% of the utilization was postextubation.
HFNC was utilized in 27% of all pediatric ICU admissions for a wide range of indications. Development of protocols for the initiation, escalation, and weaning of HFNC would optimize the utilization.
高流量鼻导管(HFNC)在儿科中的应用越来越广泛,可为导致缺氧和呼吸窘迫的呼吸系统疾病输送加湿空气和氧气。在新生儿重症监护病房(ICU),它与更好的耐受性、更低的并发症和更低的成本相关。关于儿科ICU中使用HFNC的适应症以及需要使用HFNC的疾病/病理的流行病学数据很少。
本研究是一项回顾性队列研究,研究对象为2011年10月1日至2013年10月31日入住一家三级儿童医院儿科ICU并接受HFNC治疗的患者。采用描述性统计来描述人口统计学和使用数据。采用检验比较来比较数据。
在研究入组期间,共管理了620例接受HFNC治疗的患者,占ICU总入院人数的27%。平均年龄为3.74岁(范围0 - 18.1岁),患者中44%为女性,65%为非裔美国人。报告的使用HFNC的主要适应症为哮喘持续状态(24%)、哮喘持续状态合并肺炎(17%)和细支气管炎(16%)。在以哮喘持续状态为主要诊断入院的患者中,41%需要使用特布他林进行治疗。在334例接受HFNC治疗的患者(53.8%)中,通过聚合酶链反应检测到呼吸道病毒感染,其中260例患者鼻病毒/肠道病毒检测呈阳性。与所有其他呼吸道病毒疾病相比,鼻病毒/肠道病毒感染的患者需要更高的峰值流量(14.9 L对13.1 L,P = 0.01);然而,这是一个年龄较大的人群,两组之间的峰值氧浓度没有差异(49.8%对47.1%,P = 0.25)。16%的患者将HFNC用作拔管后支持。在63例先天性心脏病患者中,92%的使用是在拔管后。
在所有儿科ICU入院患者中,27%因各种适应症使用了HFNC。制定HFNC启动、升级和撤机的方案将优化其使用。